However, recurrence occurs earlier in hormone receptor-negative cases (HER2 subtype and triple negative breast cancer) than in cases of the luminal subtype (Metzger-Filho et al. 2013), and the timing of recurrence is strongly influenced by hormonal sensitivity (Makita et al. 2014). Here, ERBB2 is linked to triple-negative breast carcinoma.